FDA rejects J&J premature ejaculation drug

Share this article:
The FDA has rejected Johnson & Johnson's application for its experimental drug to treat premature ejaculation, the company said yesterday.
J&J's Alza unit said it plans to address the questions raised by the FDA in its not approvable letter and continue developing the drug.
Alza did not provide further details on why the FDA did not approve the drug.
In a statement, the J&J unit said it "continues to believe that dapoxetine provides important benefits for men who suffer from (premature ejaculation)."
Currently, there are no FDA approved drugs on the market to treat premature ejaculation, a distinct medical condition recognized by the American Urological Association, among other groups.
Share this article:

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.